Biocytogen Pharmaceuticals (Beijing) Past Earnings Performance
Past criteria checks 0/6
Biocytogen Pharmaceuticals (Beijing) has been growing earnings at an average annual rate of 5.6%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 26.8% per year.
Key information
5.6%
Earnings growth rate
22.7%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 26.8% |
| Return on equity | -32.8% |
| Net Margin | -30.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Biocytogen Pharmaceuticals (Beijing) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 801 | -244 | 347 | 388 |
| 31 Mar 24 | 759 | -313 | 348 | 431 |
| 31 Dec 23 | 717 | -383 | 349 | 474 |
| 30 Sep 23 | 674 | -451 | 339 | 547 |
| 30 Jun 23 | 632 | -519 | 329 | 619 |
| 31 Mar 23 | 583 | -561 | 321 | 659 |
| 31 Dec 22 | 534 | -602 | 314 | 699 |
| 30 Sep 22 | 493 | -585 | 283 | 687 |
| 30 Jun 22 | 453 | -569 | 252 | 675 |
| 31 Mar 22 | 404 | -557 | 241 | 617 |
| 31 Dec 21 | 355 | -546 | 230 | 558 |
| 31 Dec 20 | 254 | -217 | 277 | 276 |
Quality Earnings: 2315 is currently unprofitable.
Growing Profit Margin: 2315 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2315 is unprofitable, but has reduced losses over the past 5 years at a rate of 5.6% per year.
Accelerating Growth: Unable to compare 2315's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2315 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: 2315 has a negative Return on Equity (-32.76%), as it is currently unprofitable.